Maximus
MMS
55.65
+0.97
+1.77%
Maximus
US · MMS
#2545 by market cap
Listed 1970
55.65
+0.97
+1.77%
Live - 5344 symbols - heartbeat 78s ago
· 2026-10-07 20:02
After-hours
56.00
+0.63%
- Market cap
- 2.91B
- P/E (TTM)i
- 8.23
- P/Bi
- 1.67
- EPSi
- 5.51
- Div yieldi
- 2.26%
- 52W posi
- 10%
Reader sentiment
Are you bullish or bearish on MMS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.00, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +2.36% YoY
Margins
- Gross margin
- 24.55%
- Operating margin
- 9.73%
- Net margin
- 5.87%
Key ratios & quality
- Enterprise valuei
- 4.06B
- PEG ratioi
- 0.51
- Altman Z-Scorei
- 3.00
PEG uses trailing P/E against the 3-year net income growth rate (16.11%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.39B | 2.89B | 3.46B | 4.25B | 4.63B | 4.90B | 5.31B | 5.43B |
| Gross profit | 594.39M | 671.18M | 711.00M | 946.98M | 939.81M | 1.03B | 1.25B | 1.33B |
| Selling & admin expenses | 285.24M | 321.02M | 387.09M | 494.09M | 534.49M | 639.22M | 671.58M | 713.11M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 298.84M | 317.11M | 288.28M | 408.53M | 314.85M | 294.79M | 488.50M | 528.29M |
| Pretax profit | 299.21M | 317.32M | 287.06M | 383.68M | 277.10M | 210.29M | 406.51M | 444.85M |
| Tax | 78.39M | 76.83M | 72.55M | 92.48M | 73.27M | 48.50M | 99.60M | 125.82M |
| Net profit | 220.82M | 240.50M | 214.51M | 291.20M | 203.83M | 161.79M | 306.91M | 319.03M |
| Basic EPS | 3 | 4 | 3 | 5 | 3 | 3 | 5 | 6 |
| Diluted EPS | 3.35 | 3.72 | 3.39 | 4.67 | 3.29 | 2.63 | 4.99 | 5.51 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.36B | 1.35B | 1.32B | 1.35B | 1.31B | 1.28B |
| Gross profit | 338.82M | 359.51M | 333.55M | 318.67M | 342.26M | 348.80M |
| Selling & admin expenses | 162.86M | 170.83M | 187.68M | 152.16M | 173.48M | 167.19M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 152.97M | 165.67M | 122.86M | 146.21M | 148.49M | 161.43M |
| Pretax profit | 132.46M | 142.97M | 100.47M | 126.27M | 126.53M | 138.16M |
| Tax | 35.89M | 36.99M | 25.18M | 32.32M | 28.47M | 34.57M |
| Net profit | 96.57M | 105.98M | 75.29M | 93.94M | 98.06M | 103.59M |
| Basic EPS | 2 | 2 | 1 | 2 | 2 | 2 |
| Diluted EPS | 1.69 | 1.86 | 1.32 | 1.70 | 1.80 | 1.95 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 808.63M | 789.43M | 932.56M | 1.08B | 1.03B | 1.06B | 1.20B | 1.25B |
| Cash & ST investments | 369.51M | 105.57M | 71.74M | 135.06M | 40.66M | 65.41M | 183.12M | 222.35M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.46B | 1.75B | 2.02B | 4.12B | 3.99B | 3.99B | 4.13B | 4.07B |
| Total current liabilities | 277.45M | 364.24M | 561.17M | 789.43M | 774.45M | 723.01M | 807.53M | 765.16M |
| Short-term debt | 136.00K | 9.66M | 91.63M | 156.63M | 127.46M | 136.70M | 87.80M | 91.29M |
| Long-term debt | -- | 231.00K | 18.02M | 1.43B | 1.29B | 1.16B | 1.09B | 1.28B |
| Total liabilities | 375,581,000.00 | 497,531,000.00 | 782,883,000.00 | 2,638,636,000.00 | 2,443,343,000.00 | 2,317,962,000.00 | 2,288,693,000.00 | 2,395,604,000.00 |
| Total equity | 1.09B | 1.25B | 1.24B | 1.48B | 1.55B | 1.67B | 1.84B | 1.67B |
| Retained earnings | 633.28M | 794.74M | 770.50M | 987.83M | 1.03B | 1.12B | 1.28B | 1.06B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.33B | 1.61B | 1.25B | 1.42B | 1.51B | 1.64B |
| Cash & ST investments | 108.06M | 59.78M | 222.35M | 137.59M | 157.45M | 56.95M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 4.20B | 4.46B | 4.07B | 4.21B | 4.24B | 4.37B |
| Total current liabilities | 721.24M | 706.15M | 765.16M | 608.05M | 681.69M | 678.07M |
| Short-term debt | 85.84M | 88.15M | 91.29M | 95.79M | 99.33M | 109.88M |
| Long-term debt | 1.45B | 1.61B | 1.28B | 1.51B | 1.47B | 1.57B |
| Total liabilities | 2,532,298,000.00 | 2,689,257,000.00 | 2,395,604,000.00 | 2,488,488,000.00 | 2,542,213,000.00 | 2,626,228,000.00 |
| Total equity | 1.67B | 1.77B | 1.67B | 1.72B | 1.70B | 1.74B |
| Retained earnings | 1.07B | 1.16B | 1.06B | 1.11B | 1.08B | 1.11B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 316.77M | 356.73M | 244.59M | 517.32M | 289.84M | 314.34M | 515.26M | 429.37M |
| Depreciation & amortization | 62.19M | 85.46M | 100.16M | 90.72M | 132.80M | 149.32M | 125.53M | 133.72M |
| Free cash flow | 290.25M | 289.88M | 203.89M | 480.76M | 233.69M | 223.65M | 401.07M | 366.16M |
| Dividends paid | -11.69M | -63.89M | -70.16M | -68.84M | -68.72M | -68.07M | -72.90M | -68.71M |
| Stock buybacks / issuance | -66.92M | -47.45M | -166.96M | -3.36M | -96.12M | 0 | -73.07M | -447.48M |
| Ending cash balance | 356.56M | 116.49M | 88.56M | 156.57M | 136.80M | 122.09M | 235.76M | 260.46M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 42.71M | -182.72M | 649.37M | -244.40M | 189.53M | -124.99M |
| Depreciation & amortization | 32.44M | 32.62M | 37.17M | 33.19M | 32.63M | 32.06M |
| Free cash flow | 25.51M | -198.21M | 641.85M | -250.67M | 179.02M | -136.97M |
| Dividends paid | -16.90M | -16.90M | -16.85M | -16.34M | -17.82M | -17.28M |
| Stock buybacks / issuance | -77.85M | 0 | -141.04M | -40.56M | -114.44M | -49.92M |
| Ending cash balance | 155.94M | 105.38M | 260.46M | 179.53M | 244.70M | 153.25M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 21.81 | 20.66 | 17.23 | 21.39 | 13.46 | 10.06 | 17.48 | 18.14 |
| ROA %i | 15.70 | 15.02 | 11.38 | 9.48 | 5.03 | 4.06 | 7.56 | 7.78 |
| ROIC %i | 21.89 | 20.68 | 15.24 | 13.02 | 7.61 | 7.36 | 11.88 | 12.16 |
| 5-year avg ROE %i | 25.32 | 24.10 | 22.14 | 21.18 | 18.91 | 16.56 | 15.93 | 16.11 |
| EBIT margin %i | 12.55 | 11.09 | 8.35 | 9.36 | 6.98 | 6.00 | 9.21 | 9.74 |
| FCF / sales %i | 12.42 | 10.04 | 5.89 | 11.30 | 5.05 | 4.56 | 7.56 | 6.74 |
| Current ratioi | 2.91 | 2.17 | 1.66 | 1.37 | 1.33 | 1.46 | 1.49 | 1.64 |
| Quick ratioi | 2.76 | 2.00 | 1.53 | 1.24 | 1.10 | 1.26 | 1.32 | 1.47 |
| Debt / assetsi | 0.01 | 0.57 | 10.55 | 41.46 | 37.72 | 35.86 | 30.91 | 35.49 |
| LT debt / equityi | -- | 0.02 | 9.83 | 104.77 | 88.98 | 77.50 | 64.53 | 80.82 |
| Interest coveragei | 300.21 | 108.31 | 140.42 | 27.02 | 7.03 | 3.50 | 5.93 | 6.29 |
| Revenue CAGR (3Y) %i | 4.44 | 6.30 | 12.20 | 21.16 | 17.06 | 12.32 | 7.64 | 5.46 |
| Net income CAGR (3Y) %i | 11.85 | 10.53 | 0.80 | 9.67 | -5.41 | -8.97 | 1.77 | 16.11 |
| FCF CAGR (3Y) %i | 42.14 | 29.45 | -13.25 | 18.32 | -6.93 | 3.13 | -5.86 | 16.15 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 17.36 | 17.61 | 18.14 | 22.09 | 22.19 | 21.11 |
| ROA %i | 7.28 | 7.47 | 7.78 | 8.99 | 8.85 | 8.40 |
| ROIC %i | 11.09 | 11.27 | 12.16 | 13.32 | 13.29 | 12.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 9.16 | 9.55 | 9.74 | 10.97 | 10.99 | 11.06 |
| FCF / sales %i | 4.06 | -- | 6.74 | 4.07 | 7.00 | 8.25 |
| Current ratioi | 1.84 | 2.27 | 1.64 | 2.34 | 2.21 | 2.42 |
| Quick ratioi | 1.68 | 2.11 | 1.47 | 2.12 | 1.96 | 2.17 |
| Debt / assetsi | 38.58 | 39.90 | 35.49 | 39.69 | 38.40 | 39.66 |
| LT debt / equityi | 92.01 | 95.45 | 80.82 | 91.55 | 90.07 | 93.19 |
| Interest coveragei | 6.21 | 6.35 | 6.29 | 6.75 | 6.64 | 6.51 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Program Operations is the largest reported line at 47.13% of revenue, across 4 reported segments.
- Clinical services follows at 43.24%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Program Operations47.13%
Clinical services43.24%
Technology Solutions5.26%
Employment and Other4.37%
Quote time 2026-10-07 20:02:33 · For reference only, not investment advice and not tailored to your situation.